In studies of more than 900 people by Mannick and her team, RTB101 and drugs like it bolstered aging immune systems, cut risk for respiratory diseases and may have lowered the risk of urinary tract infections. A version of the RTB101 drug could win Food and Drug Administration (FDA) approval as early as 2021 for a single, age-related health threat: the winter colds, flu, pneumonia and other respiratory tract infections that send over 1 million older adults to the hospital every year and kill more than 75,000. Studies of the drug as a preventive for Parkinson's disease are set for later this year, with additional research looking into its effect in reducing heart failure being eyed for some time in the future.
In studies of more than 900 people by Mannick and her team, RTB101 and drugs like it bolstered aging immune systems, cut risk for respiratory diseases and may have lowered the risk of urinary tract infections. A version of the RTB101 drug could win Food and Drug Administration (FDA) approval as early as 2021 for a single, age-related health threat: the winter colds, flu, pneumonia and other respiratory tract infections that send over 1 million older adults to the hospital every year and kill more than 75,000. Studies of the drug as a preventive for Parkinson's disease are set for later this year, with additional research looking into its effect in reducing heart failure being eyed for some time in the future.